We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Novel Method for Detecting Lung Cancer

By LabMedica International staff writers
Posted on 10 Oct 2011
A highly sensitive technology can detect lung cancer by identifying a specific small ribonucleic acid (microRNA) in the bloodstream, according to a new study.

Researchers at the University of Missouri (MU; Columbia, USA) used a nanopore sensor based on the α-haemolysin protein to detect selectively microRNAs at the single molecular level in plasma samples from lung cancer patients, without the need for labels or amplification of the microRNA. More...
When the target microRNA interacts with the functionalized lumen of the nanopore channel, it blocks the ion pathway in a characteristic way. The resulting conductance changes allow for the identification and quantification of the targeted single molecules in the mixture.

The nanopore sensor, which uses a programmable oligonucleotide probe to generate the target-specific signature signal, can quantify sub-picomolar levels of microRNAs, and can even distinguish single-nucleotide differences between specific microRNA family members. The nanopore sensors themselves can be assembled through genetic engineering using protein ion channels, and can alternatively be artificially fabricated on solid substrates using fashion nanotechnology. The study describing the technology was published in the October 2, 2011, issue of Nature Nanotechnology.

“While there are many research labs that focus on nanopore applications, this is the first time that nanopore technology has been used to detect lung cancer,” said corresponding author Li-Qun Gu, PhD, an associate professor of biological engineering. “This technology could possibly be used in the future to detect other cancer types, as well as other types of diseases with specific DNA or RNA in the blood.”

Related Links:

University of Missouri





Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Homocysteine Quality Control
Liquichek Homocysteine Control
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.